There are many diabetes treatments available on the market from insulin to insulin-like medications. In this article we will be comparing two the biggest names when it comes to insulin – Fiasp and Humalog.
Fiasp & Humalog are two common insulin medications taken by patients with type 1 & 2 diabetes. Both of these rapid-acting insulin’s mimic insulin that is produced in the body and taken to stabilize blood sugar levels.
Rapid-acting insulin is a class of insulin medication which start working after 15 minutes of injection according to The American Diabetes Association.
Fiasp Insulin by Novo Nordisk is within the aspart category and found to be slightly faster than other types of insulin such as Novolog and Humalog. It contains niacinamide as part of its formulation which causes monomors (single pieces of insulin) to travel quickly through the subcutaneous layer faster.
In fact Fiasp insulin’s rapid-acting can enter the blood stream within 2 minutes after injection and post-meal duration can last up to 4 hours.
Injection can be taken 20 minutes before eating or even 20 minutes after to reduce the post-meal spike which is unlike other types of insulin.
The CDE has described Fiasp as working “50 percent harder” during the first 30-60 minutes in comparison to Novalog, Apidra and Humalog.
Fiasp can also be taken with an insulin pump however you’re likely to find that it requires a reduction in your total daily insulin needs and basal insulin settings since it’s more rapid-acting.
Fiasp: Is right for you?
Despite all the amazing benefits Fiasp has to offer, it may not be the best option for you. Insulin medication is not a one-size fits all solution.
According to some diabetes experts, it may not be the right choice for low-carb meals since those meals digest slower.
Patients also need to take caution when transitioning to Fiasp from other insulin medications such as Humalog, Apidra and Novolog.
If patients are using it as their primary meal-time insulin, patients must consider what they are eating and time of dosing. Otherwise this fast-acting insulin can result in low blood sugars as a result.
Fiasp: Side Effects
Like most insulin’s available on the market, hypoglycemia is one of the potential side effects.
According to Novo Nordisk, reactions that have been reported may include (but not limited to):